Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 icll-07 filo trial

View Full Paper
Ask AI
Bookmark
Share

Authors

AMAnne‐Sophie MichalletMGMagali Le Garff‐TavernierMDMarie Sarah Dilhuydy

Discussion

Loading...

Member takes

Overview

Phase 2 trial shows improved progression-free survival in chronic lymphocytic leukemia, indicating low toxicity and treatment flexibility.

Key Points

  • To evaluate the long-term outcomes of a fixed-duration immunochemotherapy strategy in CLL patients while minimizing toxicity.
  • Phase 2 trial involving untreated patients with chronic lymphocytic leukemia (CLL)
  • Administered a fixed-duration regimen combining obinutuzumab and ibrutinib, followed by consolidation therapies
  • Monitored complete remission rates and minimal residual disease levels after treatment
  • 62.2% of patients achieved complete remission with low measurable residual disease levels
  • Progression-free survival and overall survival rates were 87% and 93%, respectively
  • No increased risk of serious infections or second cancers observed among the majority of patients

Cite This Study

Michallet et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d866https://doi.org/10.1182/blood-2025-3883
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FCR-I/iven combination for CLL: «Cheap but fierce»2025
  2. 2Outcomes in high-risk subgroups after fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Up to 5.5 years of follow-up in the phase 2 CAPTIVATE study.2024 · 6 citations
  3. 3Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib2015 · 661 citations
  4. 4Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL2024 · 49 citations
  5. 5Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: Results from the randomized CLL17 trial2025 · 4 citations